Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001418812-25-000016 0001418812 XXXXXXXX LIVE 3 Class A Common Stock 07/31/2025 false 0001805284 77311W101 Rocket Companies, Inc. 1050 WOODWARD AVENUE DETROIT MI 48226 Jason Breeding,Sonia Muscatine 415-362-3700 One Letterman Drive Building D, 4th Floor San Francisco CA 94129 0001418812 N VA Partners I, LLC a OO N DE 0.00 25395627.00 0.00 25395627.00 25395627.00 N 9.9 OO (4) See Item 3 (8, 10, 11) See Item 2 and 5 (14) LLC 0001464912 N ValueAct Capital Master Fund, L.P. a WC N D8 0.00 25395627.00 0.00 25395627.00 25395627.00 N 9.9 PN (4) See Item 3 (8, 10, 11) See Item 2 and 5 0001351069 N ValueAct Capital Management, L.P. a OO N DE 0.00 25395627.00 0.00 25395627.00 25395627.00 N 9.9 PN (4) See Item 3 (8, 10, 11) See Item 2 and 5 0001351073 N ValueAct Capital Management, LLC a OO N DE 0.00 25395627.00 0.00 25395627.00 25395627.00 N 9.9 OO (4) See Item 3 (8, 10, 11) See Item 2 and 5 (14) LLC 0001418814 N ValueAct Holdings, L.P. a OO N DE 0.00 25395627.00 0.00 25395627.00 25395627.00 N 9.9 PN (4) See Item 3 (8, 10, 11) See Item 2 and 5 0001763309 N ValueAct Holdings II, L.P. a OO N DE 0.00 25395627.00 0.00 25395627.00 25395627.00 N 9.9 PN (4) See Item 3 (8, 10, 11) See Item 2 and 5 0001418813 N ValueAct Holdings GP, LLC a OO N DE 0.00 25395627.00 0.00 25395627.00 25395627.00 N 9.9 OO (4) See Item 3 (8, 10, 11) See Item 2 and 5 (14) LLC Class A Common Stock Rocket Companies, Inc. 1050 WOODWARD AVENUE DETROIT MI 48226 This Amendment No. 3 supplements the information set forth in the Schedule 13D filed by the Reporting Persons with the United States Securities and Exchange Commission (the "SEC"), as amended from time to time (the "Schedule 13D"), the Class A Common Stock (the "Common Stock") of Rocket Companies, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant. The Schedule 13D is hereby supplementally amended as follows: The source of funds used for the purchase of the Issuer's securities was the working capital of ValueAct Master Fund. The aggregate purchase price of the Common Stock beneficially owned by the ValueAct Master Fund is approximately $324,555,682.57. Set forth below is the beneficial ownership of shares of Common Stock of the Issuer for each person named in Item 2. Shares reported as beneficially owned by ValueAct Master Fund are also reported as beneficially owned by (i) ValueAct Management L.P. as the manager of each such investment partnership, (ii) ValueAct Management LLC, as General Partner of ValueAct Management L.P., (iii) ValueAct Holdings, as the majority owner of the membership interests of VA Partners I, (iv) ValueAct Holdings II, as the sole owner of the limited partnership interests of ValueAct Management L.P. and the membership interests of ValueAct Management LLC, and (v) ValueAct Holdings GP, as General Partner of ValueAct Holdings and ValueAct Holdings II. Shares reported as beneficially owned by ValueAct Master Fund are also reported as beneficially owned by VA Partners I, as General Partner of ValueAct Master Fund. VA Partners I, ValueAct Management L.P., ValueAct Management LLC, ValueAct Holdings, ValueAct Holdings II, and ValueAct Holdings GP also, directly or indirectly, may own interests in one or more than one of the partnerships from time to time. Unless otherwise indicated below, by reason of such relationship ValueAct Master Fund is reported as having shared power to vote or to direct the vote, and shared power to dispose or direct the disposition of, such shares of Common Stock, with VA Partners I (only with respect to ValueAct Master Fund), ValueAct Management L.P., ValueAct Management LLC, ValueAct Holdings, ValueAct Holdings II, and ValueAct Holdings GP. As of the date hereof, the Reporting Persons may be deemed to be the beneficial owner of 25,395,627 shares of Common Stock, representing approximately 9.9% of the Issuer's outstanding Common Stock. All percentages set forth in this Schedule 13D are based upon 254,664,311 shares of Common Stock, which is the sum of (a) the Issuer's reported 151,272,632 outstanding shares of Common Stock as of May 2, 2025 as reported in the Issuer's Form 10-Q for the fiscal period ended March 31, 2025, and (b) 103,391,679 shares of Common Stock of the Issuer that Redfin Corporation's ("Redfin") stockholders will receive pursuant to the Issuer's all-stock acquisition of Redfin as reported in the Issuer's Form 8-K dated July 1, 2025. The response to Item 5(a) is incorporated herein by reference. Information concerning transactions in the Common Stock of the Issuer effected since the date of the previous filing to this Schedule 13D by the Reporting Persons is set forth in Exhibit 1 attached hereto and is incorporated herein by reference. Not applicable. Not applicable. Exhibit 1: Transactions in Securities of the Issuer VA Partners I, LLC /s/ Jason B. Breeding Jason B. Breeding, Authorized Signatory 08/04/2025 ValueAct Capital Master Fund, L.P. /s/ Jason B. Breeding Jason B. Breeding, Authorized Signatory, VA Partners I, LLC, its General Partner 08/04/2025 ValueAct Capital Management, L.P. /s/ Jason B. Breeding Jason B. Breeding, Authorized Signatory, ValueAct Capital Management, LLC, its General Partner 08/04/2025 ValueAct Capital Management, LLC /s/ Jason B. Breeding Jason B. Breeding, Authorized Signatory 08/04/2025 ValueAct Holdings, L.P. /s/ Jason B. Breeding Jason B. Breeding, Authorized Signatory, ValueAct Holdings GP, LLC, its General Partner 08/04/2025 ValueAct Holdings II, L.P. /s/ Jason B. Breeding Jason B. Breeding, Authorized Signatory, ValueAct Holdings GP, LLC, its General Partner 08/04/2025 ValueAct Holdings GP, LLC /s/ Jason B. Breeding Jason B. Breeding, Authorized Signatory 08/04/2025